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FACTORS PREDICTING ALLOGENEIC PERIPHERAL BLOOD STEM CELL
(PBSC) MOBILIZATION AFTER G-CSF TREATMENT IN HEALTHY DONORS
Brissot, E.1, Chevallier, P.1, Guillaume, T.1, Delaunay, J.1, Ayari, S.1,
Saulquin, B.1, Flandrois, G.2, Devys, A.2, Stocco, V.2, Moreau, P.1,
Harousseau, J.L.1, Mohty, M.1 1CHU de Nantes, Nantes, France;
2Etablissement Francais du Sang (EFS), Nantes, France
Some healthy donors may show poor mobilization response to G-
CSF and poor CD341 apheresis yields. Therefore, identifying do-
nors at risk for poor mobilization could be of value in optimising
transplantation approaches. This single centre report analyzed fac-
tors associated with PBSC mobilization and yield in a homogeneous
caucasian population (n 5 95; 53% males) of healthy adult donors.
All donors received G-CSF dosed at 10 mg/kg/d for 5 days followed
by large volume leukapheresis. 69 donors (73%) were healthy sibling
donors, while 26 (27%) were healthy volunteer donors for HLA-
identical unrelated transplants. All donors were undergoing their
first PBSC mobilization. Donors’ demographic characteristics
were as follow (median; range): age, 47 (18–81) y., weight, 69 (43–
106) kg, height, 170(150–187) cm, body-mass index (BMI), 23.9
(15.2–35.7) kg/m2. As per institutional policy, the targeted total
number of CD341 stem cells was between 4 and 8 10e6/kg recip-
ient body weight to be collected in a maximum of 3 apheresis ses-
sions. Overall, the median number of collected CD341 cells was
6.25  10e6/kg (range, 1.7–16.6), with 16 donors (17%) yielding
less than 4  10e6/kg CD341 cells. In univariate analysis, female
gender, lower weight, height, pre-G-CSF and post G-CSF Hb
levels, and low CD341 cell counts prior to first apheresis, were as-
sociated with significantly lower total CD341 stem cells yields
(\6.25  10e6/kg). In multivariate analysis, male donor gender
and higher post-G-CSF CD341 cell counts prior to the first apher-
esis were most strongly associated with a higher total number of
collected CD341 stem cells (OR 5 6.17, 95%CI (2.39–15.93),
P5 0.0001; and OR5 3.95, 95%CI (1.53–10.19), P5 0.004 respec-
tively). Also, when considering the group of 16 ‘‘poor’’ mobilising
donors (CD341 stem cells yield\4 10e6/kg), inmultivariate anal-
ysis, we found that a higher post-G-CSF CD341 cell count prior to
the first apheresis was the strongest parameter significantly associ-
ated with a higher total number of collected CD341 stem cells
(OR5 6.36, 95%CI (1.68–24.15), P5 0.006). These results indicate
that a quick assessment of risk for poor mobilization response in
healthy donors can be achieved through simple demographic and
routine parameters. Knowledge of predictive factors for mobiliza-
tion to G-CSF may be of high interest, with the development of
newer mobilizing agents like CXCR4 antagonists.117
CORD BLOOD STORAGE FOLLOWING COLLECTION: IMPACT ON VOLUME
REDUCTION AND CRYOPRESERVATION
Morin, H.1, Wagner, E.2, Champagne, M.A.3 1CHU Sainte-Justine,
Montreal, QC, Canada; 2Centre Hospitalier Universitaire de Quebec,
Quebec, QC, Canada; 3Hema-Quebec, St-Laurent, QC, Canada
Delays from cord blood (CB) collection to processing and cryo-
preservation vary among CB banks and optimal CB storage length
and conditions are still poorly defined. Only about 25% of the
collected CB units contain a total nucleated cell (TNC) content
$1  109, providing enough cells to transplant a 40 kg recipient.
Our preliminary results suggest that CB is best stored at 4C for
up to 3 days without significant losses in cell numbers and viability.
We tested whether pre-cryopreservation CB storage conditions
impact cell recovery and viability after processing and cryopreserva-
tion. CB units were collected and processed and cryopreserved either
on the day of collection (day 0) or after a 3-day storage at 4C or
room temperature (RT). They were volume-reduced by buffy coat
separation (Optipress II) or red cell sedimentation (Hespan). Pro-
cessed CB units were cryopreserved and stored for 1 month before
thawing and washing, and were assessed for TNC, mononucleated
cell (MNC) and CD341 cell recovery, and CD451 and CD341
cell viability. Storage at RT for 3 days induced a significant loss in
TNC and MNC after processing whereas storage at 4C did not in-
duce a significant change compared to units processed on day 0. Both
Optipress II- and Hespan-processed CB units showed low CD451
cell viabilities when stored at RT (e.g. 64 6 10% at RT and 82 68% at 4C vs 986 2% on day 0, p\0.002 vs day 0 for the Optipress
group). Interestingly, CB units stored at RT for 3 days showed re-
duced TNC, MNC and CD341 cell recoveries and reduced
CD341 cell viability upon thawing and washing compared to units
cryopreserved on day 0 or stored at 4C for 3 days (e.g. CD341
cell viability in the Optipress group: 70 6 14% at RT, 87 6 10%
at 4C vs 846 5% on day 0, p\0,03 vs day 0). These results indicate
that prolonged storage at RT prior to cryopreservation can nega-
tively impact CB cell recovery and viability after processing and
upon thawing and washing of cryopreserved units.118
TREATMENT OF THREATENING REJECTION AFTER UMBILICAL CORD
BLOOD TRANSPLANTATION WITH EX VIVO EXPANDED CB DERIVED T
CELLS
Uhlin, M., Okas, M., Gertow, J., Ringden, O., Mattsson, J. Karolinska
Institutet, Stockholm, Sweden
For patients lacking a human leukocyte antigen (HLA)-matched
donor, umbilical cord blood (UCB) is a promising source of hema-
topoetic stem cells. Greater HLA disparity can be tolerated between
the recipient and donor UCB compared with bone marrow or
peripheral blood stem cells because of the naive and immature phe-
notype of UCB derived T cells. The risk of rejection is increased
after UCB transplantation. After HLA-identical sibling or matched
unrelated SCT the graft-versus-leukemia (GVL) effect may be in-
creased by donor lymphocyte infusion (DLI) after SCT. However,
after UCB transplantation DLI is not possible. This raised the ques-
tion of whether ex vivo expanded CB lymphocytes (CBL) also can be
used as a tool for adoptive immunotherapy after CB SCT. We have
managed to establish a protocol for massive expansion of CB derived
T cells making them usable in the clinic suitable for DLI after CB
transplantation. We have further been able to show that the expan-
sion protocol doesn’t skew the T cell population regarding the phe-
notype, CD4:CD8 ratio as well as TCR usage profile measured by
spectratyping. By activating the cells we have further investigated
and confirmed the expanded T cells capacity to efficiently produce
pro-inflammatory cytokines and respond in an allogeneic setting.
We have now tried expanded CBLs in an adult patient with AML
with threatening rejection after double UCB transplantation. The
patient received Bu/Cy and ATG as conditioning therapy. He was
transplanted with double UCB with a total nucleated cell dose of
5  107/kg. Both UCB units were 5/6 matched for HLA-A,-B and
-DRB1 with low resolution HLA-typing. Chimerism analysis one
month after transplant showed mixed chimerism in T-, B- and mye-
loid cells of both donor units and recipient. At four months after
transplant the patient had 85% recipient cells in both T cells and
myeloid cells indicating a threatening rejection. However, in bone
marrow CD341 cells were 90% of donor origin. Due to anticipated
rejection the patient was treated with expanded CBLs, 5 103/kg at
4 months, 1 104/kg at 5 months and 1 105/kg at six months. Im-
munusuppression was tapered at six months. The immunemodula-
tory treatment was well tolerated with no development of GVHD.
So far no change in chimeric pattern has been shown. The immune-
modulatory treatment will be continued with increasing doses of
CBLs.119
STANDARDIZATION OF T CELL (CD31) DOSE FOR ALLOGENEIC
PERIPHERAL BLOOD STEM CELL GRAFTS
Innis-Shelton, R., Tilden, A., Ashraf, K., Vaughan, W.P., Lamb, L.S.
University of Alabama at Birmingham, Birmingham, AL
The number of CD31 cells collected from donors varies widely
and no significant attempts have been made to standardize the graft
T cell content within the different categories of stem cell sources.
Preliminary data from our center have shown that that administra-
tion of dexamethasone during the last three days of G-CSF mobili-
zation reduces the donor T cell content of the graft by approximately
0.5 log, also resulting in a significant decrease in the incidence and
severity of acute GvHD. Based on these findings, we have developed
a procedure to standardize the graft to deliver a PBSC product with
a T cell dose of 3.0 6 0.5  107 CD31 cells/kg recipient body
